You just read:

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD(1)

News provided by

Boehringer Ingelheim (Canada) Ltd.

Nov 27, 2019, 08:00 ET